In This Section

Program

Friday, October 2, 2020

Saturday, October 3, 2020

Sunday, October 4, 2020

Monday, October 5, 2020

Friday, October 2, 2020

Opening Keynote Session
5-6:30 p.m.

Title to be announced
Kenneth C. Anderson, Dana-Farber Cancer Center, Boston, Massachusetts

Welcome Reception
6:30-8:30 p.m.

Saturday, October 3, 2020

Continental Breakfast
7-8 a.m.
Plenary Session 1: Dissecting the Risk of Progression of Precursor Conditions
8-9:45 a.m.

Title to be announced
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, New York

How to identify the risk of progression to MM for patients with MGUS or SMM?
María-Victoria Mateos, University Hospital of Salamanca, Salamanca, Spain

1 short talk from proffered abstract

Panel Discussion

Break
9:45-10:15 a.m.
Plenary Session 2: Genomics and Epigenetics of Myeloma
10:15 a.m.-12:20 p.M.

Genomics of multiple myeloma
Brian Walker, Indiana University, Indianapolis, Indiana

Segmenting myeloma into clinically relevant groups using genetics
Faith E. Davies, NYU Langone Health, New York, New York

Genetic features underlying high-risk multiple myeloma
Jonathan J. Keats, TGen (The Translational Genomics Research Institute), Phoenix, Arizona

Deciphering multiple myeloma complexity using whole genome sequencing
Francesco Maura, Memorial Sloan Kettering Cancer Center, New York, New York

1 short talk from proffered abstract

Panel Discussion

Free Time / Lunch on Own
12:20-3 p.m.
Plenary Session 3: Myeloma Microenvironment and Immunity
3-4:45 p.m.

Title to be announced
Madhav V. Dhodapkar, Emory University School of Medicine, Atlanta, Georgia

Title to be announced
Gad Getz, The Broad Institute of MIT and Harvard, Massachusetts General Hospital, Boston, Massachusetts

Additional speaker to be announced

1 short talk from proffered abstract

Panel Discussion

Poster Session A / Reception
5-7 p.m.

Sunday, October 4, 2020

Continental Breakfast
7-8 a.m.
Plenary Session 4: Functional Genomics and In Vivo Models
8-9:45 a.m.

Functional genomics studies to define treatment-resistance mechanisms and therapeutic targets
Constantine S. Mitsiades, Dana-Farber Cancer Institute, Boston, Massachusetts

Modeling therapy in the Vk*MYC model of multiple myeloma
Marta Chesi, Mayo Clinic Arizona, Scottsdale, Arizona

Additional speaker to be announced

1 short talk from proffered abstract

Panel Discussion

Break
9:45-10:15 a.m.
Plenary Session 5: Diagnosis, Monitoring, and Prognosis of Myeloma
10:15 a.m.-12 p.m.

Next-generation flow for diagnosis, monitoring, and prognosis of myeloma
Bruno Paiva, University de Navarra, Pamplona, Spain

Imaging in myeloma
Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Monitoring multiple myeloma with cell-free DNA
Salomon Manier, University of Lille, Lille, France

1 short talk from proffered abstract

Panel Discussion

Poster Session B / Lunch
12-2 p.m.
Panel Discussion: Bench to Bedside – Clinical Trials and Drug Development in Myeloma
2-3:30 p.m.

Title to be announced
Kenneth C. Anderson, Dana-Farber Cancer Center, Boston, Massachusetts

Title to be announced
Peter F. Lebowitz, Janssen R&D, Spring House, Pennsylvania

Translating the myeloma genome to the clinic
Daniel Auclair, Multiple Myeloma Research Foundation, Norwalk, Connecticut

Why I would agree to accrual to a myeloma clinical trial, and why I would not
James L. Omel, Independent Myeloma Research Advocate, Grand Island, Nebraska

Additional panelist to be announced

Break
3:30-3:45 P.M.
Plenary Session 6: Drug Resistance
3:45-5:30 p.m.

Single-cell immune profiling to unravel resistance to anti-CD38 therapy in myeloma
Paola Neri, University of Calgary, Calgary, AB, Canada

Factors controlling the response to BCL2 family inhibitors in myeloma
Lawrence H. Boise, Emory University, Winship Cancer Institute, Atlanta, Georgia

Intra-tumor heterogeneity in multiple myeloma and it’s role in therapeutic evasion
Rodger E. Tiedemann, Princess Margaret Cancer Center, Toronto, ON, Canada

1 short talk from proffered abstract

Panel Discussion

Monday, October 5, 2020

Continental breakfast
7-8 a.m.
Plenary Session 7: Immunotherapy
9-9:45 a.m.

Title to be announced
Noopur Raje, Massachusetts General Hospital, Boston, Massachusetts

Title to be announced
Adam D. Cohen, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Additional speaker to be announced

1 short talk from proffered abstract

Panel Discussion

Break
9:45-10:15 a.m.
Plenary Session 8: Novel Agents and Combination Therapy
10:15 a.m.-12 p.m.

Novel agents in aggressive relapse
Francesca Gay, University of Torino, Torino, Italy

Title to be announced
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany

Title to be announced
Paula Rodríguez-Otero, University de Navarra, Pamplona, Spain

1 short talk from proffered abstract

Panel Discussion

Closing Remarks / Departure
12 p.m.